PMID- 19050419
OWN - NLM
STAT- MEDLINE
DCOM- 20090115
LR  - 20151119
IS  - 1535-2811 (Electronic)
IS  - 1535-2811 (Linking)
VI  - 7
IP  - 4
DP  - 2008 Dec
TI  - Paclitaxel-eluting versus bare-metal stents in acute ST elevation myocardial 
      infarction (STEMI).
PG  - 232-8
LID - 10.1097/HPC.0b013e3181805e0b [doi]
AB  - INTRODUCTION: Data comparing efficacy and safety of drug eluting stents (DES), 
      particularly paclitaxel stent with bare metal stents (BMS) in the setting of 
      acute ST elevation myocardial infarction (STEMI) is limited and inconclusive. The 
      aim of our study is to compare the efficacy and safety of paclitaxel stent with 
      bare metal stent in acute STEMI. METHODS: A retrospective cohort study was 
      performed on patients from our single community hospital who participated in the 
      C-PORT trial from January 2003 to May 2005. One hundred forty-three patients 
      treated exclusively with either BMS or paclitaxel DES were included (79 with 
      paclitaxel DES and 64 with BMS) and were followed at 1, 3, and 6 months. The 
      primary outcome was occurrence of major adverse cardiac events defined as cardiac 
      death, STEMI or NSTEMI or the need for target vessel revascularization. Variables 
      were compared using appropriate statistics and event free survival curves were 
      estimated. RESULTS: Baseline clinical characteristics in BMS and paclitaxel DES 
      groups were well matched. No statistical difference between BMS and DES groups in 
      the rate of cardiac death (6% vs. 9%, P = 0.56), STEMI or NSEMI (1.6% vs. 1.3% 
      respectively, P = 0.88) and composite end point (13% vs. 10%, P = 0.65) was 
      observed while a significant reduction in target vessel revascularization was 
      seen in DES group (6% vs. 0% respectively, P = 0.02) was noticed. CONCLUSION: In 
      our patient group with acute STEMI, the use of paclitaxel DES did not show 
      significant decrease in cumulative end points, cardiac mortality and recurrent 
      STEMI or NSTEMI compared with BMS over a 6-month follow-up period. However, a 
      significant reduction in revascularization of target vessel was seen.
FAU - Hamirani, Yasmin S
AU  - Hamirani YS
AD  - Department of Internal Medicine, St Agnes Hospital, Baltimore, MD, USA. 
      yasminshamshuddin@yahoo.com
FAU - Jibrin, Ismaila
AU  - Jibrin I
FAU - Abraham, Daniel
AU  - Abraham D
FAU - Merriman, Barry
AU  - Merriman B
FAU - Wenz, Charlene
AU  - Wenz C
FAU - Bahr, Raymond D
AU  - Bahr RD
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Crit Pathw Cardiol
JT  - Critical pathways in cardiology
JID - 101165286
RN  - 0 (Metals)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Aged
MH  - Angioplasty, Balloon, Coronary/*instrumentation/methods
MH  - Cohort Studies
MH  - Coronary Angiography
MH  - Critical Pathways/standards/trends
MH  - *Drug-Eluting Stents
MH  - *Electrocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Metals
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Myocardial Infarction/diagnosis/mortality/*therapy
MH  - Paclitaxel/therapeutic use
MH  - Probability
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
MH  - Statistics, Nonparametric
MH  - Stents
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2008/12/04 09:00
MHDA- 2009/01/16 09:00
CRDT- 2008/12/04 09:00
PHST- 2008/12/04 09:00 [pubmed]
PHST- 2009/01/16 09:00 [medline]
PHST- 2008/12/04 09:00 [entrez]
AID - 10.1097/HPC.0b013e3181805e0b [doi]
PST - ppublish
SO  - Crit Pathw Cardiol. 2008 Dec;7(4):232-8. doi: 10.1097/HPC.0b013e3181805e0b.